GrippeCanadaV3, Main, Exploration, bibRecord, 000873

[Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].

Identifieur interne : 000873 ( Main/Exploration ); précédent : 000872; suivant : 000874

[Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].

Auteurs : Yue-Mei Hu [République populaire de Chine] ; Han-Hua Fang ; Gui-Hua Gao ; Xue-Feng Zhang ; Yi-Ju Zhang ; Shi-Wei Zhu ; Feng-Cai Zhu

Source :

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi [ 0254-6450 ] ; 2005.

RBID : pubmed:16335001

Descripteurs français

KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Canada, Effets secondaires indésirables des médicaments (immunologie), Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Facteurs temps, Femelle, Humains, Injections, Jeune adulte, Mâle, Nourrisson, Orthomyxoviridae (immunologie), Production d'anticorps (immunologie), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (effets indésirables), Vaccins antiviraux (immunologie).
MESH :
- administration et posologie : Vaccins antiviraux.
- effets indésirables : Vaccins antiviraux.
- immunologie : Effets secondaires indésirables des médicaments, Orthomyxoviridae, Production d'anticorps, Vaccins antiviraux.
- Adolescent, Adulte, Adulte d'âge moyen, Canada, Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Facteurs temps, Femelle, Humains, Injections, Jeune adulte, Mâle, Nourrisson.
Wicri :
- geographic : Canada.

English descriptors

KwdEn :
- Adolescent, Adult, Age Factors, Antibody Formation (immunology), Canada, Child, Child, Preschool, Drug-Related Side Effects and Adverse Reactions (immunology), Female, Humans, Infant, Injections, Male, Middle Aged, Orthomyxoviridae (immunology), Time Factors, Viral Vaccines (administration & dosage), Viral Vaccines (adverse effects), Viral Vaccines (immunology), Young Adult.
MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , adverse effects : Viral Vaccines.
- chemical , immunology : Viral Vaccines.
- geographic : Canada.
- immunology : Antibody Formation, Drug-Related Side Effects and Adverse Reactions, Orthomyxoviridae.
- Adolescent, Adult, Age Factors, Child, Child, Preschool, Female, Humans, Infant, Injections, Male, Middle Aged, Time Factors, Young Adult.

Abstract

OBJECTIVE

To evaluate the safety and immunogenicity of Canada split influenza virus vaccine.

METHODS

Cluster samples were by randomly chosen and divided into split vaccination group and homoimported influenza vaccination group.

RESULTS

After injection, fever-reaction and local reaction rates of 'trial' group were found as 3.69% and 1.75% respectively, but no statistical significance was found when compared with 'control' group. However the antibody positive rates of 'trail' and 'control' groupsappeared statistically significant (H1N1: 96.8% vs. 92.3%, H3N2: 95.8% vs. 90.2%, B: 52.3% vs. 62.3%). For geometric mean titer (GMT) of type H1N1, H3H2 and B antibody, 'trial' group and 'control' group increased 22.4, 16.8, 8.2 and 21.2, 12.5 and 7.4 times respectively. The antibody protective rates of type H1N1, H3N2 and B were 99%, 99% and 53.9% for 'trial' group, and 96.2%, 98.4% and 62.3% for 'control' but with no statistically significant difference.

CONCLUSION

Influenza split vaccine made in Shire company in Canada was safe and with good immunogenicity.

PubMed: 16335001

Affiliations:

République populaire de Chine

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000939
to stream Main, to step Curation: 000939

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].</title>
<author><name sortKey="Hu, Yue Mei" sort="Hu, Yue Mei" uniqKey="Hu Y" first="Yue-Mei" last="Hu">Yue-Mei Hu</name>
<affiliation wicri:level="1"><nlm:affiliation>Jiangsu Provincial Center of Disease Control and Prevention, Nanjing 210009, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Jiangsu Provincial Center of Disease Control and Prevention, Nanjing 210009</wicri:regionArea>
<wicri:noRegion>Nanjing 210009</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fang, Han Hua" sort="Fang, Han Hua" uniqKey="Fang H" first="Han-Hua" last="Fang">Han-Hua Fang</name>
</author>
<author><name sortKey="Gao, Gui Hua" sort="Gao, Gui Hua" uniqKey="Gao G" first="Gui-Hua" last="Gao">Gui-Hua Gao</name>
</author>
<author><name sortKey="Zhang, Xue Feng" sort="Zhang, Xue Feng" uniqKey="Zhang X" first="Xue-Feng" last="Zhang">Xue-Feng Zhang</name>
</author>
<author><name sortKey="Zhang, Yi Ju" sort="Zhang, Yi Ju" uniqKey="Zhang Y" first="Yi-Ju" last="Zhang">Yi-Ju Zhang</name>
</author>
<author><name sortKey="Zhu, Shi Wei" sort="Zhu, Shi Wei" uniqKey="Zhu S" first="Shi-Wei" last="Zhu">Shi-Wei Zhu</name>
</author>
<author><name sortKey="Zhu, Feng Cai" sort="Zhu, Feng Cai" uniqKey="Zhu F" first="Feng-Cai" last="Zhu">Feng-Cai Zhu</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16335001</idno>
<idno type="pmid">16335001</idno>
<idno type="wicri:Area/Main/Corpus">000939</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000939</idno>
<idno type="wicri:Area/Main/Curation">000939</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000939</idno>
<idno type="wicri:Area/Main/Exploration">000939</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].</title>
<author><name sortKey="Hu, Yue Mei" sort="Hu, Yue Mei" uniqKey="Hu Y" first="Yue-Mei" last="Hu">Yue-Mei Hu</name>
<affiliation wicri:level="1"><nlm:affiliation>Jiangsu Provincial Center of Disease Control and Prevention, Nanjing 210009, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Jiangsu Provincial Center of Disease Control and Prevention, Nanjing 210009</wicri:regionArea>
<wicri:noRegion>Nanjing 210009</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fang, Han Hua" sort="Fang, Han Hua" uniqKey="Fang H" first="Han-Hua" last="Fang">Han-Hua Fang</name>
</author>
<author><name sortKey="Gao, Gui Hua" sort="Gao, Gui Hua" uniqKey="Gao G" first="Gui-Hua" last="Gao">Gui-Hua Gao</name>
</author>
<author><name sortKey="Zhang, Xue Feng" sort="Zhang, Xue Feng" uniqKey="Zhang X" first="Xue-Feng" last="Zhang">Xue-Feng Zhang</name>
</author>
<author><name sortKey="Zhang, Yi Ju" sort="Zhang, Yi Ju" uniqKey="Zhang Y" first="Yi-Ju" last="Zhang">Yi-Ju Zhang</name>
</author>
<author><name sortKey="Zhu, Shi Wei" sort="Zhu, Shi Wei" uniqKey="Zhu S" first="Shi-Wei" last="Zhu">Shi-Wei Zhu</name>
</author>
<author><name sortKey="Zhu, Feng Cai" sort="Zhu, Feng Cai" uniqKey="Zhu F" first="Feng-Cai" last="Zhu">Feng-Cai Zhu</name>
</author>
</analytic>
<series><title level="j">Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi</title>
<idno type="ISSN">0254-6450</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Age Factors</term>
<term>Antibody Formation (immunology)</term>
<term>Canada</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Drug-Related Side Effects and Adverse Reactions (immunology)</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Injections</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Orthomyxoviridae (immunology)</term>
<term>Time Factors</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (adverse effects)</term>
<term>Viral Vaccines (immunology)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Canada</term>
<term>Effets secondaires indésirables des médicaments (immunologie)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Facteurs de l'âge</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Injections</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Orthomyxoviridae (immunologie)</term>
<term>Production d'anticorps (immunologie)</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (effets indésirables)</term>
<term>Vaccins antiviraux (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term>
<term>Orthomyxoviridae</term>
<term>Production d'anticorps</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Formation</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Age Factors</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Injections</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Canada</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Facteurs de l'âge</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Injections</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>To evaluate the safety and immunogenicity of Canada split influenza virus vaccine.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>Cluster samples were by randomly chosen and divided into split vaccination group and homoimported influenza vaccination group.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>After injection, fever-reaction and local reaction rates of 'trial' group were found as 3.69% and 1.75% respectively, but no statistical significance was found when compared with 'control' group. However the antibody positive rates of 'trail' and 'control' groupsappeared statistically significant (H1N1: 96.8% vs. 92.3%, H3N2: 95.8% vs. 90.2%, B: 52.3% vs. 62.3%). For geometric mean titer (GMT) of type H1N1, H3H2 and B antibody, 'trial' group and 'control' group increased 22.4, 16.8, 8.2 and 21.2, 12.5 and 7.4 times respectively. The antibody protective rates of type H1N1, H3N2 and B were 99%, 99% and 53.9% for 'trial' group, and 96.2%, 98.4% and 62.3% for 'control' but with no statistically significant difference.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Influenza split vaccine made in Shire company in Canada was safe and with good immunogenicity.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16335001</PMID>
<DateCompleted><Year>2010</Year>
<Month>05</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-6450</ISSN>
<JournalIssue CitedMedium="Print"><Volume>26</Volume>
<Issue>7</Issue>
<PubDate><Year>2005</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi</Title>
<ISOAbbreviation>Zhonghua Liu Xing Bing Xue Za Zhi</ISOAbbreviation>
</Journal>
<ArticleTitle>[Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].</ArticleTitle>
<Pagination><MedlinePgn>503-6</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the safety and immunogenicity of Canada split influenza virus vaccine.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Cluster samples were by randomly chosen and divided into split vaccination group and homoimported influenza vaccination group.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">After injection, fever-reaction and local reaction rates of 'trial' group were found as 3.69% and 1.75% respectively, but no statistical significance was found when compared with 'control' group. However the antibody positive rates of 'trail' and 'control' groupsappeared statistically significant (H1N1: 96.8% vs. 92.3%, H3N2: 95.8% vs. 90.2%, B: 52.3% vs. 62.3%). For geometric mean titer (GMT) of type H1N1, H3H2 and B antibody, 'trial' group and 'control' group increased 22.4, 16.8, 8.2 and 21.2, 12.5 and 7.4 times respectively. The antibody protective rates of type H1N1, H3N2 and B were 99%, 99% and 53.9% for 'trial' group, and 96.2%, 98.4% and 62.3% for 'control' but with no statistically significant difference.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Influenza split vaccine made in Shire company in Canada was safe and with good immunogenicity.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName>
<ForeName>Yue-mei</ForeName>
<Initials>YM</Initials>
<AffiliationInfo><Affiliation>Jiangsu Provincial Center of Disease Control and Prevention, Nanjing 210009, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fang</LastName>
<ForeName>Han-hua</ForeName>
<Initials>HH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Gui-hua</ForeName>
<Initials>GH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Xue-feng</ForeName>
<Initials>XF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Yi-ju</ForeName>
<Initials>YJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhu</LastName>
<ForeName>Shi-wei</ForeName>
<Initials>SW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhu</LastName>
<ForeName>Feng-cai</ForeName>
<Initials>FC</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Zhonghua Liu Xing Bing Xue Za Zhi</MedlineTA>
<NlmUniqueID>8208604</NlmUniqueID>
<ISSNLinking>0254-6450</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007267" MajorTopicYN="N">Injections</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>12</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>5</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>12</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16335001</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><noCountry><name sortKey="Fang, Han Hua" sort="Fang, Han Hua" uniqKey="Fang H" first="Han-Hua" last="Fang">Han-Hua Fang</name>
<name sortKey="Gao, Gui Hua" sort="Gao, Gui Hua" uniqKey="Gao G" first="Gui-Hua" last="Gao">Gui-Hua Gao</name>
<name sortKey="Zhang, Xue Feng" sort="Zhang, Xue Feng" uniqKey="Zhang X" first="Xue-Feng" last="Zhang">Xue-Feng Zhang</name>
<name sortKey="Zhang, Yi Ju" sort="Zhang, Yi Ju" uniqKey="Zhang Y" first="Yi-Ju" last="Zhang">Yi-Ju Zhang</name>
<name sortKey="Zhu, Feng Cai" sort="Zhu, Feng Cai" uniqKey="Zhu F" first="Feng-Cai" last="Zhu">Feng-Cai Zhu</name>
<name sortKey="Zhu, Shi Wei" sort="Zhu, Shi Wei" uniqKey="Zhu S" first="Shi-Wei" last="Zhu">Shi-Wei Zhu</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Hu, Yue Mei" sort="Hu, Yue Mei" uniqKey="Hu Y" first="Yue-Mei" last="Hu">Yue-Mei Hu</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000873 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000873 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:16335001
   |texte=   [Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:16335001" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

[Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].

[Evaluation on the safety and immunogenicity of Canada split influenza virus vaccine].

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki